

TABLE OF CONTENTS

LIST OF ABBREVIATIONS AND ACRONYMS.....	XXII
LIST OF FIGURES	XXIX
LIST OF TABLES	XXXIII
I. INTRODUCTION	1
1. CANCER.....	3
1.1. CONCEPT.....	3
1.2. MOLECULAR FEATURES OF CANCER CELLS	3
1.3. EPIDEMIOLOGY	5
2. LUNG CANCER.....	7
2.1. EPIDEMIOLOGY AND RISK FACTORS	7
2.2. PHYSIOLOGY OF THE LUNG	11
2.3. DIAGNOSIS, STAGING AND PROGNOSIS	12
2.3.1. DIAGNOSIS	12
2.3.2. STAGING AND PROGNOSIS	14
2.4. HISTOPATHOLOGICAL CLASSIFICATION	17
2.4.1. SMALL CELL LUNG CANCER (SCLC).....	18
2.4.2. NON-SMALL CELL LUNG CANCER (NSCLC).....	19
2.4.2.1. Lung adenocarcinoma - LUAD	19
2.4.2.2. Lung squamous cell carcinoma - LUSC	20
2.4.2.3. Large cell carcinoma - LCC	22
2.4.3. NEUROENDOCRINE TUMORS (NETS)	22

2.5. MOLECULAR CLASSIFICATION OF LUNG CANCER.....	23
2.5.1. MOLECULAR CLASSIFICATION OF SCLC	24
2.5.2. MOLECULAR CLASSIFICATION OF NSCLC.....	24
2.5.2.1. LUAD genomic alterations	25
2.5.2.2. LUSC genomic alterations.....	26
2.5.2.3. Alterations common to both NSCLC subtypes ...	27
2.6. NSCLC TREATMENT	28
3. CELLULAR CLONALITY AND TUMOR HETEROGENEITY	31
3.1. MODELS OF TUMOR HETEROGENEITY.....	31
3.2. CSC PROPERTIES AND TUMOR MICROENVIRONMENT.....	33
3.3. 3D <i>IN VITRO</i> MODELS	34
4. LIQUID BIOPSY	38
4.1. EXTRACELLULAR VESICLES.....	40
4.1.1. GENERAL FEATURES, CLASSIFICATION AND NOMENCLATURE	40
4.1.1.1. Exosomes	41
4.1.2. BIOGENESIS AND SECRETION	42
4.1.3. EXOSOMES CARGO	45
4.2. EXOSOMES IN CANCER.....	48
4.2.1. EXOSOMES AS A REGULATORS OF TME	50
4.2.1.1. Exosomes role in tumor angiogenesis.....	52
4.2.2. EXOSOMES IN METASTATIC NICHES	53

4.2.3. EXOSOMES IN TUMOR PROLIFERATION AND CHEMORESISTANCE	55
4.3. NSCLC-DERIVED EXOSOMES	57

II. OBJECTIVES AND HYPOTHESIS61

III. MATERIALS & METHODS65

1. MATERIALS 67

1.1 RECRUITED PATIENTS..... 67

1.1.1. TISSUE SAMPLES 67

1.1.2. BLOOD SAMPLES 68

1.2 ESTABLISHMENT OF PRIMARY CELL CULTURES..... 68

1.3 COMMERCIAL NSCLC CELL LINES 69

2. METHODS 71

2.1 CELL CULTURE GROWTH CONDITIONS 71

2.2 EXOSOMES CHARACTERIZATION 71

2.2.1. EXOSOME ISOLATION FROM CELL CULTURES 71

2.2.2. EXOSOMES ISOLATION FROM PLASMA SAMPLES 72

2.2.3. NANOPARTICLE TRACKING ANALYSIS (NTA)..... 73

2.2.4. NEGATIVE-STAINING AND TRANSMISSION ELECTRON MICROSCOPY OF EXOSOMES 74

2.2.5. IMMUNOBLOTTING 75

2.2.6. FLOW CYTOMETRY ANALYSIS 76

2.3. NUCLEIC ACIDS ISOLATION.....	77
2.3.1. RNA ISOLATION AND INTEGRITY.....	77
2.3.1.1. Exosomes from cell cultures.....	77
2.3.1.2. Exosomes from plasma.....	77
2.3.1.3. Fresh tissue from NSCLC cohort.....	78
2.3.2 DNA ISOLATION FROM CELL CULTURES/PLASMA-DERIVED EXOSOMES.....	78
2.4. DETERMINATION OF THE MUTATIONAL STATUS.....	79
2.4.1 EXOSOMAL MUTATIONAL STATUS FROM ESTABLISHED NSCLC CULTURES.....	79
2.4.1.1. Mutational status determination by BEAMing digital PCR.....	79
2.4.1.2. Detection of ALK rearrangements by RT-qPCR...	80
2.4.2 EXOSOMAL MUTATIONAL STATUS FROM BLOOD SAMPLES OF NSCLC PATIENTS.....	80
2.5. GENE EXPRESSION ANALYSIS.....	82
2.5.1. WHOLE MRNA EXPRESSION PROFILING OF EXOSOMES DERIVED FROM CELL CULTURES.....	82
2.5.2. DEGS VALIDATION USING RT-QPCR.....	84
2.5.3. GENE EXPRESSION PANEL IN PLASMA-DERIVED EXOSOMES.....	86
2.5.3.1 Data Normalization and Analysis.....	88
2.6. IMMUNOFLUORESCENCE ANALYSIS.....	89
2.7. IMMUNOHISTOCHEMICAL ANALYSIS.....	89
2.8. IN SILICO DATASET VALIDATION.....	90

2.9. STATISTICAL ANALYSIS	91
2.10. OTHER STATISTICAL METHODS.....	91

IV. RESULTS AND DISCUSSION.....93

CHAPTER 1: CELL CULTURES 95

1.1. CHARACTERIZATION OF EXOSOMES DERIVED FROM NSCLC CELL CULTURES	95
1.2. MUTATIONAL STATUS OF EXOSOMES DERIVED FROM CELL CULTURES	107
1.3. DIFFERENTIAL EXPRESSION PROFILES OF TUMOR CELL CULTURES-DERIVED EXOSOMES	108
1.3.1. DEGS IN EXOSOMES FROM 2D VS 3D MODELS	109
1.3.1.1. Differential expressed miRNAs in exosomes from 2D vs 3D	113
1.3.2. DEGS IN EXOSOMES FROM LUAD and LUSC.....	115
1.3.2.1. Differential expressed miRNAs in exosomes from LUAD and LUSC.....	120
1.3.3. DEGS IN EXOSOMES FROM CELL LINES VS PRIMARY CULTURES.....	126
1.4. DEGs VALIDATION IN TUMOR CELL CULTURES-DERIVED EXOSOMES	128
1.4.1. DEGs VALIDATION IN EXOSOMES FROM 3D vs 2D CULTURES.....	128
1.4.2. DEGs VALIDATION IN EXOSOMES FROM LUAD AND LUSC CULTURES	133

1.5. IN-SILICO VALIDATION OF EXOSOMAL BIOMARKERS IN NSCLC	141
1.6. VALIDATION OF EXOSOMAL BIOMARKERS IN A RESECTED NSCLC COHORT.....	145
CHAPTER 2: PLASMA	153
2.1. CHARACTERIZATION OF EXOSOMES DERIVED FROM NSCLC PLASMATIC SAMPLES.....	153
2.2. MUTATIONAL STATUS DETERMINATION THROUGH LIQUID BIOPSY ELEMENTS	156
2.3. ANALYSIS OF PLASMA EXO-mRNA FOR BIOMARKERS DETECTION	164
V. INTEGRATION OF RESULTS	177
VI. CONCLUSIONS	185
VII. REFERENCES	189
VIII. ANNEXES	227
A. SUPPLEMENTARY MATHERIAL	229
B. FUNDING	238
C. COMMUNICATIONS TO NATIONAL AND INTERNATIONAL CONFERENCES	238

D. AWARDS.....	241
E. PUBLICATIONS DURING THE DOCTORAL THESIS	242
F. APPROVAL FROM THE INSTITUTIONAL ETHICAL AND SCIENTIFIC REVIEW BOARD.	244
G. INFORMED CONSENT DOCUMENT.....	247